[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Haseki Training and Research Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":379},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,46,76,105,126,154,182,203,223,243,262,282,303,330,353],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054192","predictors-of-rebound-hyperbilirubinemia-study-100054192",false,"NCT07694635","Predictors of Rebound Hyperbilirubinemia Study","Predictors of Rebound Hyperbilirubinemia After Phototherapy in Neonates","Inclusion Criteria:\n\n* Neonates admitted to the NICU with neonatal hyperbilirubinemia\n* Gestational age ≥35 weeks\n* Requirement for phototherapy according to institutional protocol and current guideline-based phototherapy thresholds\n* Receipt of standard and\u002For intensive phototherapy\n* Availability of bilirubin measurements before, during, and after phototherapy\n* Availability of rebound bilirubin measurement within 48 hours after phototherapy discontinuation\n* Written informed consent obtained from parents or legal guardians, if required by the ethics committee\n\nExclusion Criteria:\n\n* Major congenital anomalies\n* Conjugated hyperbilirubinemia\n* Neonates requiring exchange transfusion before completion of initial phototherapy\n* Severe perinatal asphyxia\n* Proven or suspected inborn errors of metabolism affecting bilirubin metabolism\n* Significant congenital liver disease\n* Neonates transferred to another center before completion of rebound bilirubin follow-up\n* Missing or incomplete clinical or laboratory data\n* Absence of rebound bilirubin measurement within 48 hours after phototherapy discontinuation\n* Parents or legal guardians declining participation, if consent is required","ALL","2 Hours","28 Days",{"count":20,"type":21},300,"ESTIMATED","2 Days","OBSERVATIONAL","\\## Brief Summary\n\nNeonatal hyperbilirubinemia is one of the most common causes of neonatal hospitalization and phototherapy treatment. Although phototherapy is highly effective, rebound hyperbilirubinemia following discontinuation of phototherapy may occur in some infants and may require repeat treatment. Early identification of neonates at risk for clinically significant rebound hyperbilirubinemia could help optimize discharge timing and reduce unnecessary hospital stay and repeat bilirubin testing.\n\nThis prospective observational study aims to evaluate the predictors of rebound hyperbilirubinemia after phototherapy discontinuation in neonates admitted to the NICU. Particular focus will be placed on the role of delta total serum bilirubin (ΔTSB), defined as the difference between the phototherapy threshold and the measured bilirubin level at the time of phototherapy discontinuation. Clinical, demographic, laboratory, hemolytic, feeding-related, and phototherapy-related variables will also be analyzed.\n\nThe primary outcome will be clinically significant rebound hyperbilirubinemia requiring repeat phototherapy within 24-48 hours after discontinuation of the initial phototherapy treatment. Secondary outcomes include rebound bilirubin levels, duration of hospitalization, and factors associated with repeat phototherapy.",[26,27],"Neonatal Hyperbilirubinemia","Rebound Hyperbilirubinemia",[27,29,30,31,32],"Neonatal Jaundice","Phototherapy","Neonate","Repeat Phototherapy","NOT_YET_RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":21},"2026-06-15",{"date":41,"type":21},"2026-11",{"name":43,"class":44},"Haseki Training and Research Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100626990","oral-vs-intravenous-dexamethasone-in-total-knee-arthroplasty-100626990","NCT07442812","Oral vs Intravenous Dexamethasone in Total Knee Arthroplasty","The Role of Dexamethasone in Total Knee Arthroplasty: Effects of Oral and Intravenous Administration on Early Postoperative Pain and Mobilization","TKA","Inclusion Criteria:\n\n* Age between 50 and 80 years\n* Diagnosis of primary knee osteoarthritis (primary gonarthrosis)\n* Scheduled for elective primary total knee arthroplasty\n* ASA physical status I or II\n* Ability to ambulate independently (with or without assistive devices) preoperatively\n* Ability to understand study procedures and complete pain and functional assessments\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Revision total knee arthroplasty\n* History of knee joint infection\n* Inflammatory arthritis (e.g., rheumatoid arthritis)\n* Chronic systemic corticosteroid use\n* Uncontrolled diabetes mellitus\n* Known endocrine disorders affecting glucose metabolism\n* Active infection at any site\n* Known hypersensitivity to corticosteroids\n* Severe hepatic, renal, or cardiac disease\n* Neurological or musculoskeletal disorders affecting gait or balance\n* Inability or unwillingness to comply with study procedures","50 Years","80 Years",{"count":57,"type":21},270,"This prospective observational cohort study aims to evaluate the association between perioperative dexamethasone administration and early postoperative recovery following primary total knee arthroplasty. In routine clinical practice, dexamethasone may be administered orally, intravenously, or not administered, depending on the surgeon's established perioperative protocol.\n\nThe primary objective is to assess early postoperative recovery in terms of pain intensity, functional mobility, and knee joint range of motion. Secondary objectives include evaluation of inflammatory response, postoperative metabolic changes, opioid requirement, and the severity of postoperative nausea and vomiting (PONV).\n\nGroup allocation is non-randomized and determined solely by the standard perioperative management approach routinely applied by the surgeon selected by the patient. No additional interventions are introduced for research purposes. All outcomes are assessed prospectively during the early postoperative period.",[60,61,62],"Knee Osteoarthritis","Gonarthrosis; Primary","Total Knee Arthroplasty",[62,64,60,65,66],"Intravenous Dexamethasone","Gonarthrosis","Multimodal Analgesia","RECRUITING","2026-05-19",{"date":70,"type":37},"2026-05-20",{"date":72,"type":37},"2026-03-31",{"date":74,"type":21},"2027-10",{"name":43,"class":44},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100608409","maternal-smoking-exposure-and-newborn-outcomes-a-study-using-cord-blood-cotinine-100608409","NCT07201181","Maternal Smoking Exposure and Newborn Outcomes: A Study Using Cord Blood Cotinine","Association of Prenatal Tobacco Exposure, Classified by Cord Blood Cotinine (Active, Passive, None), With Neonatal Metabolic and Physiologic Indices: A Single-Center Prospective Cohort Study","Inclusion Criteria:\n\n* Liveborn neonate delivered at the study hospital, aged 0-72 hours at assessment.\n* Routine umbilical cord blood gas available at birth (pH, base excess, lactate).\n* Cord blood cotinine available or obtainable at delivery for exposure classification.\n* Singleton live birth at ≥35 weeks of gestation.\n* Availability of routine umbilical cord blood gas parameters at birth, including at minimum pH, base excess, and lactate, with FCOHb recorded where available.\n* Availability of routine first postnatal day clinical and laboratory data according to unit practice.\n* Parent\u002Fguardian provides informed consent for use of neonatal data obtained from routine care.\n* Standard newborn assessments obtainable within 72 hours (e.g., birthweight, \\~6-hour vitals\u002FBP, TSH at 24-48 h, hearing screen ≤72 h per unit practice).\n\nExclusion Criteria:\n\n* Emergent clinical scenarios where any research step could delay urgent care.\n* Major congenital anomaly, known chromosomal\u002Fgenetic disorder, or major metabolic disease likely to affect neonatal adaptation or study outcomes.\n* Severe perinatal condition preventing acquisition of core study data or making outcome interpretation unreliable, including major birth trauma or prolonged intensive care requirement.\n* Missing cord blood cotinine measurement or missing core primary outcome data.\n* Multiple gestation.\n* Prior enrollment of the same neonate (no re-enrollment).",true,"0 Minutes","72 Hours",{"count":87,"type":21},126,"Prenatal exposure to tobacco smoke, whether from active maternal smoking or secondhand exposure, has been associated with adverse neonatal adaptation, metabolic stress, and impaired fetal oxygenation. This single-center prospective observational cohort study will quantify prenatal tobacco exposure using cord blood cotinine measured at delivery and examine its association with early neonatal biochemical, metabolic, and physiologic outcomes.\n\nParticipants will consist of mother-newborn dyads recruited consecutively at a tertiary academic hospital. After informed consent, cord blood obtained at delivery will be used for cotinine measurement. Based on pre-specified cotinine thresholds and maternal smoking history, newborns will be classified into three exposure groups: active exposure, passive exposure, or no exposure. No experimental intervention will be administered, and neonatal assessments will be based on routine perinatal and postnatal care.\n\nNeonatal data collected will include umbilical cord blood gas parameters (pH, pCO2, pO2, base excess, bicarbonate, and lactate), fetal carboxyhemoglobin (FCOHb), birthweight and anthropometric measurements, Apgar scores, oxygen saturation, heart rate, blood pressure, and routine laboratory indices obtained during the first postnatal day. These laboratory measures may include complete blood count parameters, inflammatory and hematologic ratios such as NLR and PLR, metabolic markers including albumin and lactate-to-albumin ratio, lipid parameters such as HDL and LDL, thyroid-stimulating hormone from the standard newborn screening program, and hearing screening results. Early follow-up data, including postnatal weight loss and bilirubin measurements at routine visits, will also be recorded where available. Maternal and perinatal covariates, including maternal age, parity, gestational age, delivery mode, intrapartum factors, smoking history, and relevant maternal comorbidities, will be collected to support adjusted analyses.\n\nThe primary objective is to determine whether higher cord blood cotinine-defined exposure is associated with greater metabolic stress and impaired fetal oxygenation at birth, particularly as reflected by cord lactate, related blood gas parameters, and FCOHb. Secondary objectives include evaluating associations with early neonatal hematologic, metabolic, endocrine, and clinical indices, including birthweight, blood pressure, bilirubin levels, thyroid screening results, and hearing screening outcomes.\n\nThe study will recruit consecutive eligible dyads in a prospective manner. Statistical analyses will follow a pre-specified plan and will include multivariable regression models to adjust for potential confounding factors. Sensitivity and subgroup analyses, including analyses by delivery mode and other clinically relevant strata, will be performed when feasible.\n\nThis study is designed to provide prospectively collected, biochemically verified evidence on how prenatal tobacco exposure, classified by cord blood cotinine, relates to immediate neonatal metabolic, hematologic, and physiologic outcomes using measurements that are feasible within routine clinical care.",[90,91,92,93],"Tobacco Smoke Pollution","Maternal Exposure During Pregnancy","Infant, Newborn","Carbon Monoxide Poisoning",[95,96],"Prenatal Tobacco Exposure","Maternal Smoking","2026-04-23",{"date":99,"type":37},"2026-04-29",{"date":101,"type":21},"2026-05-04",{"date":103,"type":21},"2026-10-01",{"name":43,"class":44},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":112,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":125,"locationsCount":45},"100631576","the-effect-of-magnesium-on-post-spinal-headaches-100631576","NCT07502482","The Effect of Magnesium on Post-spinal Headaches","The Effect of Intravenous Magnesium Sulphate on the Development of Post-Spinal Headache Following Caesarean Section Under Spinal Anaesthesia: A Retrospective Cohort Study","Inclusion Criteria:\n\n* • Patients aged 18-45\n\n  * Patients who underwent spinal anaesthesia for elective caesarean section\n  * Patients with an ASA physical status score of I-III\n  * Patients in whom a 25G or 27G pencil-point needle was used for spinal anaesthesia\n  * Patients with complete medical records\n\nExclusion Criteria:\n\n* • Patients undergoing emergency surgery\n\n  * Patients with a history of chronic headaches\n  * Patients who have undergone unsuccessful spinal anaesthesia or multiple attempts\n  * Patients who have undergone combined spinal-epidural anaesthesia\n  * Patients with a contraindication to magnesium sulphate\n  * Patients with insufficient medical records","FEMALE","18 Years","45 Years",{"count":20,"type":21},"This retrospective cohort study aims to assess the effect of the use of magnesium sulphate in routine clinical practice on the development of post-dural puncture headache in patients undergoing spinal anaesthesia",[118],"Post-spinal Headache","2026-04-01",{"date":121,"type":37},"2026-04-07",{"date":119,"type":21},{"date":124,"type":21},"2026-06-01",{"name":43,"class":44},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":45},"100629354","pneumoperitoneum-duration-and-bicarbonate-changes-in-laparoscopic-hernia-surgery-100629354","NCT07473583","Pneumoperitoneum Duration and Bicarbonate Changes in Laparoscopic Hernia Surgery","Association Between Pneumoperitoneum Duration and Changes in Serum Bicarbonate Levels in Patients Undergoing Laparoscopic Inguinal Hernia Repair: A Prospective Observational Study","TAPPHCO3","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients undergoing laparoscopic inguinal hernia repair using the TAPP technique\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Severe cardiovascular disease\n* Renal insufficiency\n* Patients requiring additional intra-abdominal surgical procedures\n* Strangulated inguinal hernia requiring bowel resection",{"count":135,"type":21},100,"The goal of this observational study is to learn how the length of pneumoperitoneum during laparoscopic inguinal hernia surgery may affect changes in blood bicarbonate levels. Pneumoperitoneum is the use of carbon dioxide gas to create space inside the abdomen during laparoscopic surgery.\n\nThe main question this study aims to answer is whether a longer pneumoperitoneum time is associated with changes in blood bicarbonate levels after surgery.\n\nParticipants are adults undergoing laparoscopic inguinal hernia repair as part of their routine medical care. Researchers will measure blood gas values, including bicarbonate levels, before surgery and again two hours after surgery. The change in bicarbonate levels will be compared with the duration of pneumoperitoneum during the operation.\n\nThe results of this study may help improve the understanding of metabolic changes that occur during laparoscopic surgery.",[138,139],"Hernia, Inguinal","Inguinal Hernia",[141,142,143,144,145],"Pneumoperitoneum","Laparoscopic Inguinal Hernia Repair","Serum Bicarbonate","Blood Gas Analysis","TAPP Technique","2026-03-12",{"date":148,"type":37},"2026-03-16",{"date":150,"type":21},"2026-03-10",{"date":152,"type":21},"2026-05",{"name":43,"class":44},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":165,"phases":166,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":181,"locationsCount":4},"100608604","preparing-kids-for-mri-using-vr-100608604","NCT07203716","Preparing Kids for MRI Using VR","Effect of Home-Based and Immediate Pre-Scan Virtual Reality Orientation on Motion Artifacts and Sedation Need in Pediatric MRI: A Three-Arm Randomized Controlled Trial","Inclusion Criteria:\n\n* Children 5 to 10 years old (inclusive).\n* First-ever MRI for a clinically indicated, non-emergent examination (outpatient or elective inpatient).\n* Ability to view the age-appropriate 360° VR module (head-mounted viewer or flat 360° on screen) with basic comprehension of instructions (child and\u002For caregiver in Turkish).\n* Parental\u002Fguardian informed consent and child assent per age\u002Fcompetence.\n* Standard MRI safety screening passed; institutional rescue sedation policies remain available if clinically required.\n\nExclusion Criteria:\n\n* MRI contraindications (e.g., non-MR-conditional implants, unsafe metallic foreign bodies).\n* Pre-planned sedation or general anesthesia irrespective of behavior (clinician decision made prior to randomization).\n* Conditions contraindicating VR exposure (e.g., uncontrolled epilepsy, severe motion sickness\u002Fvertigo causing intolerance).\n* Severe uncorrected visual or hearing impairment precluding module viewing or instruction adherence.\n* Emergent\u002Furgent MRI where study procedures could delay care.\n* Neurodevelopmental or behavioral conditions that render still positioning entirely unfeasible despite standard coaching (investigator judgment).\n* Prior participation in this trial (no re-enrollment).","5 Years","10 Years",{"count":164,"type":21},150,"INTERVENTIONAL",[167],"NA","Children frequently exhibit pre-MRI anxiety that can cause motion, repeated sequences, prolonged room time, and exposure to sedation. Orientation with Virtual Reality (VR) may reduce anxiety by familiarizing children with the scanner environment and expected sensations. This single-center, three-arm randomized clinical trial evaluates whether (1) Home+Booster VR (an age-appropriate 360° VR module at home \\~24-48 hours before MRI plus a brief on-site refresher immediately before positioning), (2) Pre-Scan VR only (same module viewed on site immediately before positioning), or (3) Usual Care without VR improves MRI image quality and tolerance in children undergoing their first-ever MRI.\n\nEligible participants are children scheduled for clinically indicated, non-emergent MRI with no prior MRI experience. Major exclusions comprise MRI contraindications; contraindications to VR use (e.g., uncontrolled epilepsy or severe motion sickness); uncorrected severe visual\u002Fhearing impairment precluding VR viewing; and inability to provide assent\u002Fconsent. After consent\u002Fassent, participants are randomized 1:1:1 to one of three arms. Anticipated enrollment is \\~150 total (\\~50 per arm; up to 60 per arm if feasible). All arms receive routine safety procedures and child-oriented coaching per institutional practice. The VR module (\\~8-10 minutes) provides a 360° walkthrough of the MRI process (sounds, positioning, keeping still) with child-focused narration. Adherence (timestamps\u002Fduration) is recorded where applicable.\n\nThe primary outcome is motion artifact rated on a predefined ordinal scale by a board-certified radiologist masked to allocation; the proportion achieving diagnostic quality without repeat\u002Fsedation is also reported. Key secondary outcomes include sedation requirement, number of repeated sequences, total scan room time, scan completion without interruption, and change in child anxiety (mYPAS-SF). Additional prespecified measures include comfort\u002Fcalmness Likert scales, Wong-Baker FACES pain, CEMS during scan, parent state anxiety, satisfaction VAS, physiologic vitals (heart rate, blood pressure, SpO₂) at defined peri-scan time points, observed crying and movement durations, and total scan duration. The trial uses parallel assignment with allocation concealment and masked outcome assessment. Analyses follow intention-to-treat with prespecified subgroup exploration by age bands (5-7 vs 8-10). Recruitment is planned for October 6, 2025; primary completion is expected within approximately three months.",[170,171,172,173,174],"Anxiety","Sedation","Child","Virtual Reality","MRI","2025-10-01",{"date":177,"type":37},"2025-10-02",{"date":179,"type":21},"2025-10-06",{"date":72,"type":21},{"name":43,"class":44},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":112,"minAge":113,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":4},"100598271","the-role-of-regional-analgesia-in-sleep-quality-100598271","NCT07069322","The Role of Regional Analgesia in Sleep Quality","The Role of Regional Analgesia in Sleep Quality: Evaluation of Additional Regional Block in Total Abdominal Hysterectomy Patients","Inclusion Criteria:\n\n* Elective TAH planned\n* ASA I-III group\n* Female patients aged 18-70 years\n* Those who are planned to be hospitalized at least one night in the postoperative period\n* Those who have the cognitive capacity to understand and answer the questionnaire\n\nExclusion Criteria:\n\n* Patients with a history of neurological or psychiatric disease\n* Patients diagnosed with sleep disorders\n* Patients with sedative\u002Fhypnotic drug use\n* Patients requiring additional surgical intervention during the operation\n* Patients admitted to intensive care unit\n* Patients operated with epidural or spinal anesthesia","70 Years",{"count":191,"type":21},66,"To evaluate the effect of regional analgesic blocks (TAP or rectus sheath block) applied in addition to general anesthesia on postoperative sleep quality in patients undergoing total abdominal hysterectomy (RCSQ score).",[194],"Richards-Campbell Sleep Questionnaire (RCSQ)","2025-07-07",{"date":197,"type":37},"2025-07-16",{"date":199,"type":21},"2025-07-25",{"date":201,"type":21},"2025-12-25",{"name":43,"class":44},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":112,"minAge":113,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100590904","causes-of-spinal-failure-in-cesarean-section-100590904","NCT06973486","Causes of Spinal Failure in Cesarean Section","The Effects of Social, Emotional and Attitudinal Dynamics on Spinal Anesthesia Outcomes in Cesarean Delivery","Inclusion Criteria:\n\n* spinal anesthesia for term pregnancy and cesarean section\n* age ≥ 18\n* knowing the gestational week when participating in the study\n* answering all research questions\n* using the internet and social media tools\n\nExclusion Criteria:\n\n* mental and physical disability\n* diagnosis and treatment for psychiatric disorders\n* clinically significant physical health problemı",{"count":211,"type":21},128,"The main purpose of this research is to determine the causes of spinal anesthesia failures during cesarean section due to social, emotional and attitude factors towards surgery and to use this information to improve anesthesia practice.",[214],"Causes of Spinal Failure","2025-05-22",{"date":217,"type":37},"2025-05-28",{"date":219,"type":21},"2025-05-20",{"date":221,"type":21},"2025-11-20",{"name":43,"class":44},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":112,"minAge":230,"maxAge":114,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100592881","neural-therapy-in-cesareans-100592881","NCT06999200","Neural Therapy in Cesareans","Evaluation of the Effectiveness of Subcutaneous and Intracutaneous Local Anesthesia for Postoperative Analgesia in Patients Undergoing Cesarean Section Under General Anesthesia: a Prospective Randomized Controlled Trial (RCT)","Inclusion Criteria:\n\n* Healthy pregnancy,\n* Term (\\>37 weeks) and preterm (28-34 weeks) pregnancy,\n* Cases that received general anesthesia for cesarean section,\n* Cases with and without labor,\n* Cases with and without obesity,\n* Cases that had their first or second cesarean section\n\nExclusion Criteria:\n\n* Pregnant women under 19 years of age,\n* Those with a history of allergic reactions to analgesics to be used,\n* Stillbirth,\n* Surgical complications during C\u002FS and placement of an abdominal drain,\n* No head or breech presentation during C\u002FS,\n* Occiput posterior presentation during C\u002FS,\n* Anhydramnios and polyhydramnios,\n* Allergic reactions to the drugs used in the study, alcohol dependence, drug and substance dependence, chronic pain syndrome, neuropathic pain disorder history,\n* History of clinically significant cardiovascular, pulmonary, hepatic, renal, neurological, psychiatric, metabolic disease.","19 Years",{"count":232,"type":21},156,"In the management of pain after Caesarean section (C\u002FS), opioid or nonsteroidal anti-inflammatory parenteral drugs are applied. These drugs are insufficient in some cases and may cause pain attacks during the day. Higher doses and repeated drug applications or combined drug administration may cause drug side effects and interactions. Alternative applications to provide analgesia include subcutaneous and intracutaneous local anesthetic application to the wound site. Although the effectiveness of these applications has been tested in individuals with different clinical characteristics and has been shown to be largely more successful, they have not been sufficiently introduced into routine practice. There is a need to review the pain methods suggested in the literature and develop new solutions that can be applied more optimally, improve the patient's pain management in the postoperative period, and increase their quality of life and satisfaction.\n\nIt aims to evaluate the success of subcutaneous and intracutaneous local anesthesia applications compared to traditional applications, and to find the most optimal management.",[235],"Visual Analogue Scale",{"date":237,"type":37},"2025-05-31",{"date":239,"type":21},"2025-06-10",{"date":241,"type":21},"2025-10-10",{"name":43,"class":44},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":112,"minAge":113,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":4},"100592888","ovarian-reserve-in-intensive-care-patients-100592888","NCT06999291","Ovarian Reserve in Intensive Care Patients","Evaluation of Ovarian Reserve in Critically Ill Patients Followed in the Intensive Care Unit","Inclusion Criteria:\n\n* 18-35 years of age\n* Female patients followed in the intensive care unit for more than 24 hours for internal or surgical reasons,\n* Women whose ovarian reserve is being evaluated,\n\nExclusion Criteria:\n\n* Previous ovarian surgery, endometriosis, endometrioma,\n* History of chemotherapy, radiotherapy,\n* Ovarian cyst, malignancy and other ovarian pathologies,\n* Women with single ovary,\n* Women receiving hormone therapy,\n* Polycystic ovary syndrome,\n* Surgical intervention within the last 6 months,\n* History of drug, alcohol, substance use,\n* Women in pregnancy, puerperium, lactation,\n* History of vaccination within the last 6 months","35 Years",{"count":252,"type":21},75,"Gastrointestinal, pulmonary, nephrological, cardiac, neurologic and psychological effects in critically ill patients followed in the intensive care unit have been shown in the literature. However, the effects on ovarian reserve in these patients have not been sufficiently investigated and studies investigating this issue are limited in the literature. The synthesis, release frequency and amplitude of reproductive hormones change under stress. In addition, changes in ovarian homeostasis affect ovarian reserve. The aim of this study was to evaluate ovarian reserve in critically ill patients followed up in the intensive care unit.",[255],"Anti-Mullerian Hormone Deficiency",{"date":237,"type":37},{"date":258,"type":21},"2025-06-15",{"date":260,"type":21},"2025-11-15",{"name":43,"class":44},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":83,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":4},"100588295","the-test-of-those-managing-pain-with-their-own-pain-100588295","NCT06939543","The Test of Those Managing Pain With Their Own Pain","The Test of Those Managing Pain With Their Own Pain\" - A Questionnaire-Based Study on Pain Perception and Patient Empathy Among Physicians Actively Managing Pain","Inclusion Criteria:\n\n* Specialist physicians actively working in pain treatment and management (e.g., Algology, Physical Medicine and Rehabilitation, Anesthesiology, Neurology, Rheumatology, etc.) or physicians currently undergoing specialty training in these areas.\n* Physicians who volunteer to participate in the study and sign the informed consent form.\n* Physicians who have actively followed up patients and applied pain management techniques within the last year.\n\nExclusion Criteria:\n\n* Physicians who are not actively involved in pain management or who specialize in different medical fields.\n* Physicians who do not wish to complete the questionnaire or do not provide voluntary consent.\n* Physicians who complete the questionnaire incompletely or invalidly during the study.",{"count":270,"type":21},175,"The study aims primarily to investigate physicians' awareness of their health status, empathy towards patients, and management processes through a questionnaire targeting physicians who diagnose and manage patients' pain.",[273],"Empathy","2025-04-18",{"date":276,"type":37},"2025-04-23",{"date":278,"type":21},"2025-04-11",{"date":280,"type":21},"2025-04-30",{"name":43,"class":44},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":165,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100587250","modified-thoracoabdominal-plane-block-and-rectus-block-combination-100587250","NCT06925945","Modified Thoracoabdominal Plane Block and Rectus Block Combination","Comparison of Pain Between Modified Thoracoabdominal Plane Block and Rectus Block Combination and Intraperitoneal Local Infiltration Analgesia","Inclusion Criteria:\n\n* Over 18 years old\n* ASA1-2\n* Laparoscopic cholecystectomy cases\n\nExclusion Criteria:\n\n* Bleeding disorders\n* Anticoagulant use\n* Patients with previous nerve damage\n* Lack of patient consent\n* Patients with liver and kidney failure\n* Patients allergic to local anesthetics used\n* Patients with BMI \\> 35","65 Years",{"count":291,"type":21},60,[167],"The aim of our study was to investigate the effect of the combination of Modified thoracoabdominal plane block (M-TAPA) and rectus sheath block with local infiltration analgesia on postoperative pain scores and opioid use.",[235],"2025-04-14",{"date":297,"type":37},"2025-04-17",{"date":299,"type":21},"2025-04-10",{"date":301,"type":21},"2025-08-15",{"name":43,"class":44},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":83,"sex":112,"minAge":310,"maxAge":311,"enrollmentInfo":312,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":313,"conditions":314,"keywords":317,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":45},"100578645","carotid-flow-measurements-in-pregnant-women-100578645","NCT06813989","Carotid Flow Measurements in Pregnant Women","Evaluation of the Effectiveness of Carotid Flow Measurements in Predicting Post-Spinal Hypotension in Pregnant Women","Inclusion Criteria:\n\n* \"Uncomplicated term pregnant women aged 20-40 years classified as ASA 1-2.\n\nExclusion Criteria:\n\n* Those diagnosed with preeclampsia or eclampsia or with systolic blood pressure above 160\n\nIndividuals with arrhythmia\n\nIndividuals with contraindications for spinal anesthesia\n\nIndividuals with Ba MI over 40\n\nThose with a gestational age under 36 weeks or over 41 weeks\n\nIndividuals with chronic kidney insufficiency (GRF under 60)\n\nThose with carotid stenosis or a history of previous cerebrovascular events\n\nPatients with placental anomalies\n\nThose initially planned for expected delivery but later switched to cesarean after being taken to trauma.\n\nPatients were taken to the operating room with an emergency cesarean decision\n\nIn case of failed spinal anaesthesia, those who switched to general anaesthesia before delivery","20 Years","40 Years",{"count":291,"type":21},"The goal of this observational study is to reveal the relation between carotid flow changes and post-spinal hypotension in pregnant women between the ages of 20-40. The main question it aims to answer is:\n\nDo the carotid flow blood flow measurements and corrected flow time change before and after spinal anaesthesia related to postspinal hypotension? Participants are already receiving spinal anaesthesia to receive a caesarean section. As part of their regular anaesthesia management protocol, they will answer questions about anaesthesia management. The participants will only examined by ultrasound twice.",[315,316],"Postspinal Hypotension","Pregnant Women Undergoing Cesarean Delivery",[318,319,320,321],"carotid blood flow","corrected carotid flow time","postspinal hypotension","cesarean delivery","2025-03-17",{"date":324,"type":37},"2025-03-18",{"date":326,"type":37},"2025-02-15",{"date":328,"type":21},"2025-06-01",{"name":43,"class":44},{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":55,"enrollmentInfo":337,"targetDuration":4,"studyType":165,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":45},"100535646","lidocaine-dexmedetomidine-esmolol-and-magnesium-effect-on-optic-nerve-sheath-diameter-after-laryngoscopy-100535646","NCT06254534","Lidocaine, Dexmedetomidine, Esmolol and Magnesium Effect on Optic Nerve Sheath Diameter After Laryngoscopy","Effect of Lidocaine, Dexmedetomidine, Esmolol and Magnesium Use on Optic Nerve Sheath Diameter and Hemodynamic Response After Laryngoscopy: Randomized, Controlled, Double-blind Trial","Inclusion Criteria:\n\n* Patients aged 18 to 80 years who will receive endotracheal intubation for general anesthesia and have an American Society of Anesthesiologists (ASA) Physical Status classification of I to III.\n\nExclusion Criteria:\n\n* Patients allergic to dexmedetomidine, esmolol, lidocaine, and magnesium; patients with uncontrolled hypertension or advanced heart failure with EF below 35%; patients with cardiac arrhythmia, especially Type 2 and 3 blocks, supraventricular arrhythmias. Patients with renal failure (GFR below 30) or severe liver failure; patients with known acute or previous intracranial pathology and known diagnosis of epilepsy, predefined difficult airway examination. Patients who required more than one attempt at intubation or total laryngoscopy took more than 20 seconds.",{"count":135,"type":21},[167],"This clinical trial aims to compare the effects of lidocaine, dexmedetomidine, esmolol, and magnesium on optic nerve sheath diameter and hemodynamic response to laryngoscopy.\n\nThe participants will be patients determined to need intubation and general anesthesia for any elective surgery. Each participant will receive either lidocaine, dexmedetomidine, esmolol, magnesium, or none before anesthesia induction, according to randomization. The investigator will measure the optic nerve sheath diameter by ultrasonography before and after intubation. Researchers will compare the difference between optic nerve sheath diameter, systolic blood pressure, and heart rate before and after laryngoscopy and search for the most stable group. The trial aims to determine a general anesthesia induction protocol for patients sensitive to intracranial pressure changes reflected as optic nerve sheath diameter for easy monitoring.",[341,342,343,344],"Intracranial Hypertension","Endotracheal Intubation","Optic Nerve Sheath Diameter","General Anesthesia","2025-03-16",{"date":347,"type":37},"2025-03-20",{"date":349,"type":37},"2024-02-14",{"date":351,"type":21},"2025-07",{"name":43,"class":44},{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":360,"enrollmentInfo":361,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":363,"conditions":364,"keywords":368,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":45},"100495212","point-of-care-gastric-ultrasound-for-fracture-surgery-100495212","NCT05728242","Point-of-care Gastric Ultrasound for Fracture Surgery","Perioperative Point-of-care Gastric Ultrasound for Surgical Fracture Repair: Effect of Stress on Gastric Emptying","Inclusion Criteria:\n\n* • American Society of Anesthesiologists (ASA) Physical Status classification I to III\n\n  * Patients necessitating surgery after traumatic fracture\n\nExclusion Criteria:\n\n* • Patients with a body mass index over 35\n\n  * Diseases that may lead to gastroparesis (\n  * Known gastroesophageal reflux disease\n  * Known autonomic neuropathy\n  * Known diabetes mellitus\n  * Known or operated esophageal abnormalities\n  * History of gastric surgery\n  * Acute gastric or peptic ulcus\n  * Pregnancy\n  * Preoperative narcotic analgesic usage\n  * Known connective tissue disorders like scleroderma or amyloidosis\n  * Known hiatal hernia\n  * Known gallbladder and choledochal stone","90 Years",{"count":362,"type":21},80,"Although there are fasting guidelines offered by the American Society of Anesthesiology (ASA) for managing preoperative patient assessment, some patients may need to be more cautious about the risk of aspiration. Since ultrasound has been a part of perioperative anesthesiology practice, it is simple to assess gastric content preoperatively with bedside ultrasonography (USG). More research is necessary to define elective surgeries with a possible risk of aspiration. Therefore, we aimed to evaluate the adequacy of standard fasting protocols in post-traumatic fracture surgery by measuring and evaluating gastric volume and content with USG in the preoperative operating room.",[365,366,367],"Pneumonia, Aspiration","Gastric Content","Fractures, Bone",[369,370,371,372],"gastric ultrasound","aspiration pneumonia","gastric emptying","fracture surgery",{"date":347,"type":37},{"date":375,"type":37},"2023-02-01",{"date":377,"type":21},"2025-07-30",{"name":43,"class":44},""]